Research Focused on the Global Hemophilia Market Report: 2015 Edition

Global Hemophilia Market Report: 2015 Edition Size and Share Published in 2015-05-18 Available for US$ 800 at Researchmoz.us

Description

To Browse a Full Report at: http://www.researchmoz.us/global-hemophilia-market-report-2015-edition-report.html

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.

The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.

Get a Free Sample Copy of the Report: http://www.researchmoz.us/enquiry.php?type=S&repid=281630

The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.


Table of Content

1. Overview

2. Market Analysis

2.1 Global Hemophilia Market

Market Value

Market Segmentation

2.2 Hemophilia Market by Segments

2.2.1 Hemophilia A

Market Value

Patients Treated

Regional Breakdown

Supply/Demand of Factor VIII

2.2.2 Hemophilia B

Market Value

Patients Treated

2.2.3 Hemophilia A & B with Inhibitors

Market Value

2.2.4 Von Willebrand Disease

Market Value

2.3 Regional Analysis

2.3.1 The US

Market Size

Patients Treated

Hemophilia Prevalence

2.3.2 Australia

Market Overview

Market Share

2.3.3 Europe
Market Size

Patients Treated

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Website @ www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ bit.ly/1TBmnVG

This release was published on openPR.